AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

“AstraZeneca is focused on building the transformative oncology regimens of the future,” said Polly Brown, VP, Head of Business Development, Oncology R&D. “We’re one of the few companies ...

After years of delays and rising costs, AstraZeneca has formally unveiled ... "Our ambition today is to not only unveil a building, but to also drive the next wave of scientific innovation ...

Brazilian billionaire Jorge Lemann's foundation and other business interests will fund the building of the factory ... and pharmaceutical company AstraZeneca. The Lemann Foundation said in a ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of ...